167 related articles for article (PubMed ID: 23289797)
1. Influence of lipoplex surface charge on siRNA delivery: application to the in vitro downregulation of CXCR4 HIV-1 co-receptor.
Lavigne C; Slater K; Gajanayaka N; Duguay C; Arnau Peyrotte E; Fortier G; Simard M; Kell AJ; Barnes ML; Thierry AR
Expert Opin Biol Ther; 2013 Jul; 13(7):973-85. PubMed ID: 23289797
[TBL] [Abstract][Full Text] [Related]
2. Targeted lipoplexes for siRNA delivery.
Cardoso A; Trabulo S; Moreira JN; Düzgüneş N; de Lima MC
Methods Enzymol; 2009; 465():267-87. PubMed ID: 19913172
[TBL] [Abstract][Full Text] [Related]
3. Efficient and safe delivery of siRNA using anionic lipids: Formulation optimization studies.
Kapoor M; Burgess DJ
Int J Pharm; 2012 Aug; 432(1-2):80-90. PubMed ID: 22575754
[TBL] [Abstract][Full Text] [Related]
4. Conjugating phosphospermines to siRNAs for improved stability in serum, intracellular delivery and RNAi-mediated gene silencing.
Paris C; Moreau V; Deglane G; Karim L; Couturier B; Bonnet ME; Kedinger V; Messmer M; Bolcato-Bellemin AL; Behr JP; Erbacher P; Lenne-Samuel N
Mol Pharm; 2012 Dec; 9(12):3464-75. PubMed ID: 23148419
[TBL] [Abstract][Full Text] [Related]
5. Efficacious gene silencing in serum and significant apoptotic activity induction by survivin downregulation mediated by new cationic gemini tocopheryl lipids.
Kumar K; Maiti B; Kondaiah P; Bhattacharya S
Mol Pharm; 2015 Feb; 12(2):351-61. PubMed ID: 25438085
[TBL] [Abstract][Full Text] [Related]
6. Effective siRNA delivery to inflamed primary vascular endothelial cells by anti-E-selectin and anti-VCAM-1 PEGylated SAINT-based lipoplexes.
Leus NG; Talman EG; Ramana P; Kowalski PS; Woudenberg-Vrenken TE; Ruiters MH; Molema G; Kamps JA
Int J Pharm; 2014 Jan; 459(1-2):40-50. PubMed ID: 24239833
[TBL] [Abstract][Full Text] [Related]
7. Anionic amino acid-derived cationic lipid for siRNA delivery.
Suh MS; Shim G; Lee HY; Han SE; Yu YH; Choi Y; Kim K; Kwon IC; Weon KY; Kim YB; Oh YK
J Control Release; 2009 Dec; 140(3):268-76. PubMed ID: 19567256
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4.
Zhou N; Fang J; Mukhtar M; Acheampong E; Pomerantz RJ
Gene Ther; 2004 Dec; 11(23):1703-12. PubMed ID: 15306840
[TBL] [Abstract][Full Text] [Related]
9. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
Spagnou S; Miller AD; Keller M
Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141
[TBL] [Abstract][Full Text] [Related]
10. Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS.
Cardoso AL; Simões S; de Almeida LP; Plesnila N; Pedroso de Lima MC; Wagner E; Culmsee C
J Control Release; 2008 Dec; 132(2):113-23. PubMed ID: 18796321
[TBL] [Abstract][Full Text] [Related]
11. Efficient down-regulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery.
Wang X; Yu B; Wu Y; Lee RJ; Lee LJ
Anticancer Res; 2011 May; 31(5):1619-26. PubMed ID: 21617218
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of VEGF expression in A431 and MDA-MB-231 tumour cells by cationic lipid-mediated siRNA delivery.
Briane D; Slimani H; Tagounits A; Naejus R; Haddad O; Coudert R; Charnaux N; Cao A
J Drug Target; 2012 May; 20(4):347-54. PubMed ID: 22475204
[TBL] [Abstract][Full Text] [Related]
13. Nonviral pulmonary delivery of siRNA.
Merkel OM; Kissel T
Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
[TBL] [Abstract][Full Text] [Related]
14. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
Kim HK; Davaa E; Myung CS; Park JS
Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
[TBL] [Abstract][Full Text] [Related]
15. Bacterial delivery of siRNAs: a new approach to solid tumor therapy.
Xu DQ; Zhang L; Kopecko DJ; Gao L; Shao Y; Guo B; Zhao L
Methods Mol Biol; 2009; 487():161-87. PubMed ID: 19301647
[TBL] [Abstract][Full Text] [Related]
16. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
Santel A; Aleku M; Keil O; Endruschat J; Esche V; Fisch G; Dames S; Löffler K; Fechtner M; Arnold W; Giese K; Klippel A; Kaufmann J
Gene Ther; 2006 Aug; 13(16):1222-34. PubMed ID: 16625243
[TBL] [Abstract][Full Text] [Related]
17. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of carrier-mediated siRNA delivery: lessons for the design of a stem-loop qPCR-based approach for quantification of intracellular full-length siRNA.
Colombo S; Nielsen HM; Foged C
J Control Release; 2013 Mar; 166(3):220-6. PubMed ID: 23313963
[TBL] [Abstract][Full Text] [Related]
19. Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA.
Anderson J; Banerjea A; Planelles V; Akkina R
AIDS Res Hum Retroviruses; 2003 Aug; 19(8):699-706. PubMed ID: 13678472
[TBL] [Abstract][Full Text] [Related]
20. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery.
Egorova A; Shubina A; Sokolov D; Selkov S; Baranov V; Kiselev A
Int J Pharm; 2016 Dec; 515(1-2):431-440. PubMed ID: 27789364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
